Raphael Pharmaceutical (RAPH) Liabilities and Shareholders Equity (2020 - 2026)
Raphael Pharmaceutical's (RAPH) quarterly Liabilities and Shareholders Equity came in at $7000.0 in Q2 2026, down 76.67% year-over-year from $30000.0 in Q2 2025, and down 86.79% quarter-over-quarter from $53000.0 in Q4 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Raphael Pharmaceutical has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $7000.0 for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity fell 76.67% year-over-year to $7000.0; the TTM figure through Jun 2026 stood at $97000.0 (down 51.74% YoY), while the FY2025 annual figure was $53000.0, up 96.3% from the prior year.
- Liabilities and Shareholders Equity came in at $7000.0 for Q2 2026 at Raphael Pharmaceutical, down from $53000.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $403000.0 in Q3 2023 to a low of $7000.0 in Q3 2025.
- Average Liabilities and Shareholders Equity over 5 years is $146470.6, with a median of $121000.0 recorded in 2022.
- Year-over-year, Liabilities and Shareholders Equity soared 233.06% in 2023 and tumbled 88.7% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $333000.0 in 2022, then declined by 28.23% to $239000.0 in 2023, then plunged by 88.7% to $27000.0 in 2024, then surged by 96.3% to $53000.0 in 2025, then tumbled by 86.79% to $7000.0 in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $7000.0 in Q2 2026, $53000.0 in Q4 2025, and $7000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.31 Bn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 7,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7,000.00 |
| Dec 31, 2025 | 53,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 51,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 353,000.00 |
| Dec 31, 2023 | 239,000.00 |
| Sep 30, 2023 | 403,000.00 |
| Jun 30, 2023 | 119,000.00 |
| Mar 31, 2023 | 150,000.00 |
| Dec 31, 2022 | 333,000.00 |
| Sep 30, 2022 | 121,000.00 |
| Jun 30, 2022 | 196,000.00 |
| Mar 31, 2022 | 180,000.00 |
| Dec 31, 2021 | 422,000.00 |
| Sep 30, 2021 | 62,000.00 |
| Dec 31, 2020 | 323,000.00 |